Side-by-side comparison of AI visibility scores, market position, and capabilities
Newtown PA software engineering outsourcing (NYSE: EPAM) ~$4.74B FY2024 revenue; Eastern European tech talent, Ukraine war delivery redeployment, AI coding tools, competing with Globant and Thoughtworks.
EPAM Systems, Inc. is a Newtown, Pennsylvania-based software engineering and IT services company — publicly traded on the New York Stock Exchange (NYSE: EPAM) as an S&P 500 Information Technology component — providing software product development, digital platform engineering, cloud migration, AI/ML implementation, and enterprise application services to global corporations through engineering delivery centers primarily in Poland, Hungary, India, and other Eastern European and global locations, following the forced redeployment of approximately 14,000 Ukrainian employees following Russia's February 2022 full-scale invasion of Ukraine. Prior to the war, EPAM had its largest delivery concentration in Ukraine (Kharkiv, Kyiv, Lviv — major technology talent hubs) — losing significant Ukrainian delivery capacity required rapid relocation of engineers to Poland, Czech Republic, Hungary, and other countries, demonstrating EPAM's operational resilience but creating near-term delivery disruption and cost increases. In fiscal year 2024, EPAM reported revenues of approximately $4.74 billion (-1% year-over-year) as the company navigated both the ongoing Ukraine conflict's operational complexities and the broader IT services spending slowdown affecting the sector as enterprise clients deferred discretionary technology projects. CEO Arkadiy Dobkin (co-founder, leading EPAM since 1993) has maintained EPAM's premium positioning as a "top-of-the-stack" engineering services provider — specializing in custom software product development for product companies (ISVs), digital transformation for financial services and healthcare clients, and cloud-native application engineering — rather than competing in commodity staff augmentation markets where Indian IT services firms (Infosys, Wipro) dominate on price.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.